NV-ALVARIA.
13.9.2022 15:01:49 CEST | Business Wire | Press release
Today, Alvaria, Inc. is pleased to announce the successful deployment of Alvaria Cloud™ in Google Cloud Platform (GCP). Adding GCP to their current offerings of AWS and Azure expands the available public cloud options Alvaria provides to support customer experience (CX) and employee engagement (EX) strategies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005584/en/
Alvaria CEO, Jeff Cotten rehearses "The Modern Contact Center" for opening day at ACE 2022 where he unveils a new engagement framework, The Alvaria Enterprise Modernization Journey (Photo: Business Wire)
Providing multiple public cloud selections, including GCP, is a part of the commitment Alvaria has made to provide choice for customers in order to meet their business objectives with the proper products and services. As an enterprise CCaaS vendor, Alvaria now provides industry leading support to help enterprise brands with complex and specific configuration requirements evolved to meet the needs of rapidly evolving customer expectations.
ACE 2022, Alvaria U kicks off at 9:00 AM PDT with The Modern Contact Center, an address from Chief Executive Officer, Jeff Cotten. He will unveil a new engagement framework, The Alvaria Enterprise Modernization Journey.
“We will assist customers through a process of determining business and technology objectives, with a goal of understanding where they are today and the desired end state,” said Jeff Cotten. “We will then map the best fit of products and services that align to their business goals because with Alvaria you are not going to hear and see a one-size-fits-all approach. We aim to enable choice and flexibility.”
In addition to the CEO Address, Alvaria has a full agenda planned for former Aspect Software, Noble Systems and Alvaria customers and partners including new product demonstrations, insights from industry experts, as well as product tips and tricks and a special keynote, Customer Obsession: How to Satisfy Inherently Unsatisfiable Customers, by Gibson Biddle, Entrepreneur, Advisor, Former Netflix VP Product Management.
Core to the success of ACE each year is the participation of Alvaria Partners. Alvaria would like to thank a select group of partners who have sponsored the event: Call Design, Communik.me, CS Infocomm, ITFor, Resolutte, Rich Communication Technology, Rising Interactions and Waterfield Technologies. Furthermore, this year, Alvaria introduced the ACE Partner Certified Seller track, designed to enable Alvaria partners worldwide with tools to win business.
Alvaria SVP of Global Marketing, Colleen Sheley said, “The pandemic has greatly emphasized the need for enterprises to be resilient, secure and continue to deliver exceptional customer experiences. Brands want to invest in accelerating their consumer technology initiatives and now with the deployment of Alvaria Cloud in GCP there's now less friction and more choice than ever before.”
Registration for the virtual event is still open. Get complimentary access with code: VIRTUAL-ACE22-BEMYGUEST
To register, please visit www.alvaria.com/ace
Alvaria was founded through the merger of Aspect Software and Noble Systems. We are the world leader in enterprise-scale customer experience (CX) and workforce engagement management (WEM) solutions. Our name is derived from Latin for “hives” – nature’s perfect form for millions of years – bringing you solutions that are scalable, resilient and secure, with efficiency, speed and pinpoint accuracy. ALVARIA™. Reshaping Customer Experience™. For more information, please visit www.alvaria.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005584/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom